-+ 0.00%
-+ 0.00%
-+ 0.00%

Lakewood-Amedex reports positive MIC data for Nu-3 against infected diabetic foot ulcer isolates

PUBT·09/28/2026 12:05:35
Listen to the news
Lakewood-Amedex reports positive MIC data for Nu-3 against infected diabetic foot ulcer isolates
  • Lakewood-Amedex Biotherapeutics reported positive lab data for Nu-3 against recent bacterial samples from infected diabetic foot ulcers.
  • Results were presented now, with findings supporting broad activity against resistant pathogens without detailing performance metrics.
  • Nu-3 is being tested in a Phase 2a topical trial for mildly infected diabetic foot ulcers, with topline results expected in Q1 2027.
  • Management framed the data as supportive of continued development, targeting an area with high hospitalization and amputation risk.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280802PR_NEWS_USPR_____NY57596) on September 28, 2026, and is solely responsible for the information contained therein.